We examined the association between cerebrospinal fluid (CSF)-derived biomarkers of Alzheimer’s disease and neuropsychiatric symptoms (NPS) in older non-demented adults.
We included 784 persons (699 cognitively unimpaired, 85 with mild cognitive impairment) aged ≥ 50 years who underwent CSF amyloid beta (Aβ42), hyperphosphorylated tau 181 (p-tau), and total tau (t-tau) as well as NPS assessment using Beck Depression and Anxiety Inventories (BDI-II, BAI), and Neuropsychiatric Inventory Questionnaire (NPI-Q).
Lower CSF Aβ42, and higher t-tau/Aβ42 and p-tau/Aβ42 ratios were associated with BDI-II and BAI total scores, clinical depression (BDI-II ≥ 13), and clinical anxiety (BAI ≥ 10), as well as NPI-Q–assessed anxiety, apathy, and nighttime behavior.
CSF Aβ42, t-tau/Aβ42, and p-tau/Aβ42 ratios were associated with NPS in community-dwelling individuals free of dementia. If confirmed by a longitudinal cohort study, the findings have clinical relevance of taking into account the NPS status of individuals with abnormal CSF biomarkers.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Janina Krell‐Roesch,
Martin Rakusa,
Jeremy A. Syrjanen,
Argonde C. van Harten,
Val J. Lowe,
Clifford R. Jack Jr.,
Walter K. Kremers,
David S. Knopman,
Gorazd B. Stokin,
Ronald C. Petersen,
Maria Vassilaki,
Yonas E. Geda | October 11, 2023

Wiley: Alzheimer’s & Dementia: Table of Contents